Cite
HARVARD Citation
German, P. et al. (2018). Phase 1 First‐in‐Human, Single‐ and Multiple‐Ascending Dose, and Food Effect Studies to Assess the Safety, Tolerability, and Pharmacokinetics of Presatovir for the Treatment of Respiratory Syncytial Virus Infection. Journal of clinical pharmacology. pp. 1025-1034. [Online].